Literature DB >> 20963433

Gene therapy: a viable therapeutic strategy for Parkinson's disease?

Alexander L Berry1, Thomas Foltynie.   

Abstract

Gene therapy represents a potentially useful additional technique to ameliorate the motor symptoms of Parkinson's disease (PD), and the motor complications of its treatment. The neurodegenerative process itself, as well as the non-motor symptoms of PD, both remain less amenable to most of the current gene therapy approaches. This review presents an overview of the four gene therapies in phase I/II clinical trials, outlines some of the challenges they face, and proposes additional alternative strategies that might improve the clinical prospects of gene therapy for PD. In so doing, we hope to highlight the issue of the current absence of effective treatment for non-motor symptoms of PD and the potential of further candidate targets for gene therapy intervention that might improve upon this, for both specific individuals with genetic forms of PD as well as "sporadic" PD patients.

Entities:  

Mesh:

Year:  2010        PMID: 20963433     DOI: 10.1007/s00415-010-5796-9

Source DB:  PubMed          Journal:  J Neurol        ISSN: 0340-5354            Impact factor:   4.849


  102 in total

1.  Neurturin shares receptors and signal transduction pathways with glial cell line-derived neurotrophic factor in sympathetic neurons.

Authors:  D J Creedon; M G Tansey; R H Baloh; P A Osborne; P A Lampe; T J Fahrner; R O Heuckeroth; J Milbrandt; E M Johnson
Journal:  Proc Natl Acad Sci U S A       Date:  1997-06-24       Impact factor: 11.205

2.  Delivery of neurturin by AAV2 (CERE-120)-mediated gene transfer provides structural and functional neuroprotection and neurorestoration in MPTP-treated monkeys.

Authors:  Jeffrey H Kordower; Christopher D Herzog; Biplob Dass; Roy A E Bakay; James Stansell; Mehdi Gasmi; Raymond T Bartus
Journal:  Ann Neurol       Date:  2006-12       Impact factor: 10.422

Review 3.  Drug treatment of Parkinson's disease.

Authors:  N Quinn
Journal:  BMJ       Date:  1995-03-04

4.  Role of oxidation in the neurotoxic effects of intrastriatal dopamine injections.

Authors:  T G Hastings; D A Lewis; M J Zigmond
Journal:  Proc Natl Acad Sci U S A       Date:  1996-03-05       Impact factor: 11.205

5.  Triple transduction with adeno-associated virus vectors expressing tyrosine hydroxylase, aromatic-L-amino-acid decarboxylase, and GTP cyclohydrolase I for gene therapy of Parkinson's disease.

Authors:  Y Shen; S I Muramatsu; K Ikeguchi; K I Fujimoto; D S Fan; M Ogawa; H Mizukami; M Urabe; A Kume; I Nagatsu; F Urano; T Suzuki; H Ichinose; T Nagatsu; J Monahan; I Nakano; K Ozawa
Journal:  Hum Gene Ther       Date:  2000-07-20       Impact factor: 5.695

Review 6.  Gastrointestinal dysfunction in Parkinson's disease.

Authors:  Ronald F Pfeiffer
Journal:  Lancet Neurol       Date:  2003-02       Impact factor: 44.182

7.  Phosphorylation of 4E-BP by LRRK2 affects the maintenance of dopaminergic neurons in Drosophila.

Authors:  Yuzuru Imai; Stephan Gehrke; Hua-Qin Wang; Ryosuke Takahashi; Kazuko Hasegawa; Etsuro Oota; Bingwei Lu
Journal:  EMBO J       Date:  2008-08-14       Impact factor: 11.598

8.  Safety and tolerability of putaminal AADC gene therapy for Parkinson disease.

Authors:  C W Christine; P A Starr; P S Larson; J L Eberling; W J Jagust; R A Hawkins; H F VanBrocklin; J F Wright; K S Bankiewicz; M J Aminoff
Journal:  Neurology       Date:  2009-10-14       Impact factor: 9.910

9.  Dementia and visual hallucinations associated with limbic pathology in Parkinson's disease.

Authors:  M E Kalaitzakis; L M Christian; L B Moran; M B Graeber; R K B Pearce; S M Gentleman
Journal:  Parkinsonism Relat Disord       Date:  2008-07-07       Impact factor: 4.891

10.  Comparison of transduction efficiency of recombinant AAV serotypes 1, 2, 5, and 8 in the rat nigrostriatal system.

Authors:  Nikolaus R McFarland; Jeng-Shin Lee; Bradley T Hyman; Pamela J McLean
Journal:  J Neurochem       Date:  2009-02-24       Impact factor: 5.372

View more
  10 in total

Review 1.  Gene-based therapies in Parkinson's disease.

Authors:  Patricia J Allen; Andrew Feigin
Journal:  Neurotherapeutics       Date:  2014-01       Impact factor: 7.620

Review 2.  Antioxidant gene therapy against neuronal cell death.

Authors:  Juliana Navarro-Yepes; Laura Zavala-Flores; Annadurai Anandhan; Fang Wang; Maciej Skotak; Namas Chandra; Ming Li; Aglaia Pappa; Daniel Martinez-Fong; Luz Maria Del Razo; Betzabet Quintanilla-Vega; Rodrigo Franco
Journal:  Pharmacol Ther       Date:  2013-12-12       Impact factor: 12.310

3.  The Neuroprotective Effect of Dimethyl Fumarate in an MPTP-Mouse Model of Parkinson's Disease: Involvement of Reactive Oxygen Species/Nuclear Factor-κB/Nuclear Transcription Factor Related to NF-E2.

Authors:  Michela Campolo; Giovanna Casili; Flavia Biundo; Rosalia Crupi; Marika Cordaro; Salvatore Cuzzocrea; Emanuela Esposito
Journal:  Antioxid Redox Signal       Date:  2017-01-27       Impact factor: 8.401

Review 4.  Parkinson's disease: an update on pathogenesis and treatment.

Authors:  Tom Foltynie; Joshua Kahan
Journal:  J Neurol       Date:  2013-04-16       Impact factor: 4.849

Review 5.  The role of molecular imaging in the diagnosis and management of neuropsychiatric disorders.

Authors:  Lie-Hang Shen; Yu-Chin Tseng; Mei-Hsiu Liao; Ying-Kai Fu
Journal:  J Biomed Biotechnol       Date:  2011-03-22

6.  Critical aspects of clinical trial design for novel cell and gene therapies.

Authors:  Zinovia Kefalopoulou; Iciar Aviles-Olmos; Thomas Foltynie
Journal:  Parkinsons Dis       Date:  2011-12-27

7.  Therapeutic efficacy of AAV8-mediated intrastriatal delivery of human cerebral dopamine neurotrophic factor in 6-OHDA-induced parkinsonian rat models with different disease progression.

Authors:  Lizheng Wang; Zixuan Wang; Rui Zhu; Jinpeng Bi; Xinyao Feng; Wenmo Liu; Jiaxin Wu; Haihong Zhang; Hui Wu; Wei Kong; Bin Yu; Xianghui Yu
Journal:  PLoS One       Date:  2017-06-16       Impact factor: 3.240

8.  MiR-20a-5p Regulates MPP+-Induced Oxidative Stress and Neuroinflammation in HT22 Cells by Targeting IRF9/NF-κB Axis.

Authors:  Qiang Wang; Yuan Wang; Feng Zhou; Jie Li; Gang Lu; Yingqian Zhao
Journal:  Evid Based Complement Alternat Med       Date:  2021-06-21       Impact factor: 2.629

Review 9.  Recent advances in imaging of dopaminergic neurons for evaluation of neuropsychiatric disorders.

Authors:  Lie-Hang Shen; Mei-Hsiu Liao; Yu-Chin Tseng
Journal:  J Biomed Biotechnol       Date:  2012-04-10

Review 10.  The glial response to intracerebrally delivered therapies for neurodegenerative disorders: is this a critical issue?

Authors:  Francesca Cicchetti; Roger A Barker
Journal:  Front Pharmacol       Date:  2014-07-10       Impact factor: 5.810

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.